Subscribe to our mailing list to receive research, advocacy and other updates from MS Australia
Categories
date range
MS Australia News
MS News
Why are three out of four people who develop MS women?
31 August 2026
During Women’s Health Week, MS Australia’s Deputy CEO Dr Julia Morahan details the clues that we have to solve the puzzle of why three out of four people who develop MS are women.
From our CEO: MS medication ‘rapid review’: Make your voice heard!
27 August 2026
Ahead of an upcoming PBAC stakeholder meeting on MS medicines, CEO Rohan Greenland outlines MS Australia’s key messages, including the importance of treatment choice and continued PBS access.
Have Your Say: PBAC review of MS treatments open for public consultation
27 August 2026
A public consultation is now open as part of a rapid review of PBS-listed medicines for relapsing-remitting MS. The MS community has an important opportunity to share their experiences and help ensure the lived experience of Australians with MS remains central to future PBS decisions.
Highlights from the 2026 MS Nurses Australasia Conference
27 August 2026
MS Nurses Australasia and their invited presenters shared specialist expertise and insights on MS care at their 27th Annual Conference in August 2026 in Sydney.
MS Australia LEEP members share perspectives on family screening for MS in international journal
26 August 2026
Through the lens of living with MS or caring for someone with MS, MS Australia’s lived experience expert panellists Rachel Fallis and Rebecca Small contemplate a future where family screening for MS was available.
Carol Cooke AM PLY shares her MS diagnosis story and how she's grown more comfortable with speaking up for herself in medical settings in the years since her diagnosis.
Research insights into MS, sleep and work productivity
25 August 2026
Australian research suggests some prescription medications may worsen sleep quality in people with MS. Better sleep may improve MS symptoms, work productivity and overall quality of life.
PBAC rapid review of MS medicines: what it means for the MS community
13 August 2026
Further details have now been announced about the Pharmaceutical Benefits Advisory Committee’s rapid review of medicines listed on the Pharmaceutical Benefits Scheme (PBS) for relapsing-remitting multiple sclerosis.Â
Researchers turn to lab-grown ‘mini brains’ in search of ways to repair MS damage
29 July 2026
The research, funded through MS Australia's mid-year grants round and based at The Florey Institute of Neuroscience and Mental Health, will investigate how the brain naturally produces myelin, the protective coating around nerve fibres that is damaged by MS.Â
Through its mid-year grants, MS Australia is investing early in promising research ideas and researchers at the start of their careers, to help drive the next wave of innovation and leadership in MS research.
National Pain Week: We need better answers for pain in multiple sclerosis
28 July 2026
CEO Rohan Greenland calls on the Australian Government to significantly boost support for pain and neurological research this National Pain Week, explaining why pain experienced by people living with MS is under-recognised and, too often, inadequately treated.
